• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AGA MEDICAL CORPORATION AMPLATZER SEPTAL OCCLUDER; CARDIAC OCCLUSION DEVICE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AGA MEDICAL CORPORATION AMPLATZER SEPTAL OCCLUDER; CARDIAC OCCLUSION DEVICE Back to Search Results
Model Number 9-ASD-026
Device Problem Device Operates Differently Than Expected (2913)
Patient Problem Fistula (1862)
Event Type  Injury  
Manufacturer Narrative
The results of the investigation are inconclusive since the device was not returned for analysis.A review of the device history record was not possible since the serial number was unavailable.Based on the information received, the cause of the reported incident could not be conclusively determined.
 
Event Description
The following information comes from the abstract titled "two cases of coronary artery fistula associated with deployment of amplatzer septal occluder (aso)." on an unknown date, a 26mm amplatzer septal occluder (aso) was implanted at the patient's atrial septal defect (asd) which was measured at 24.2mm.As the patient has a complication of pulmonary hypertension, she has regularly undergone coronary angiography (cag).Sixteen months after the aso was implanted, no anomalies were observed through cag.Fifteen six months after the aso was implanted, no elevation of pulmonary to systemic blood flow (qp/qs) ratio was noted.However, coronary artery fistula was confirmed from both the right and left coronary arteries toward the aso.No dilatation of coronary artery was observed compared to before the aso was implanted.The patient has been monitored.The author suggested that additional coil embolisation would be required if the coronary artery fistula become worse.The patient also has a risk of perforation due to vulnerable vessels.In order to carefully monitor signs of coronary artery fistula, a cag is likely to be needed after aso deployment.Doi: i-p04-01.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AMPLATZER SEPTAL OCCLUDER
Type of Device
CARDIAC OCCLUSION DEVICE
Manufacturer (Section D)
AGA MEDICAL CORPORATION
5050 nathan lane north
plymouth MN 55442
Manufacturer (Section G)
AGA MEDICAL CORPORATION
5050 nathan lane north
plymouth MN 55442
Manufacturer Contact
denise johnson
5050 nathan lane north
plymouth, MN 55442
6517565400
MDR Report Key6875221
MDR Text Key86574830
Report Number2135147-2017-00112
Device Sequence Number1
Product Code MLV
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P000039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Health Professional
Type of Report Initial
Report Date 09/19/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/19/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number9-ASD-026
Device Catalogue Number9-ASD-026
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/05/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age72 YR
Patient Weight55
-
-